Lexeo Therapeutics | BiotechTV

top of page

Search

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

He describes the clinical data in FA cardiomyopathy that was announced this month, and explains how the company is preparing to begin a...

Apr 23

Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease

Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease

Lexeo Therapeutics' CEO on using gene therapy for cardiovascular and Alzheimer's disease

Noland Townsend describes the science behind Lexeo's lead programs.

Feb 2, 2024

Follow BiotechTV

Also look for unique social pages for BiotechTV U.

Sponsors

NYSE_logo_large_no reg_378x197 (1).png

Learn more about our sponsors

Sponsor Spotlight

Genezen is a contract development and manufacturing organization (CDMO) with unique technical expertise in lentiviral, retroviral, and adeno-associated viral vectors. Offering process development, GMP viral vector manufacturing, and analytics, we are dedicated to helping you deliver safe, pure, and potent advanced therapies to the patients who need them.

Learn more about Genezen

bottom of page